China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market. China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed as Foundayo, could be used for chronic weight management by obese or overweight adults. GLP-1 receptor agonists are synthetic...
Health
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
South China Morning Post
The Perspectives
0 verified voices · Three viewpoints · Real discourse
Only verified Neural Identity holders can participate in The Perspectives.
Sign In with Neural Identity
Left
0
Be the first to share a left perspective
Center
0
Be the first to share a center perspective
Right
0
Be the first to share a right perspective
